Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body. E...
Eslicarbazepine acetate is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.